S&P 500 Futures
(-0.02%) 5 477.25 points
Dow Jones Futures
(-0.04%) 38 803 points
Nasdaq Futures
(0.02%) 19 925 points
Oil
(0.29%) $80.56
Gas
(1.11%) $2.82
Gold
(0.12%) $2 331.70
Silver
(-0.36%) $29.29
Platinum
(-0.13%) $969.60
USD/EUR
(0.02%) $0.932
USD/NOK
(-0.13%) $10.64
USD/GBP
(0.08%) $0.788
USD/RUB
(-1.87%) $86.80

Realaus laiko atnaujinimai Adaptimmune Therapeutics [ADAP]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta17 birž. 2024 @ 23:00

-7.23% $ 0.937

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.61% compare to its pairs and should correct upwards.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom...

Stats
Šios dienos apimtis 1.97M
Vidutinė apimtis 1.49M
Rinkos kapitalizacija 239.40M
EPS $-0.200 ( Q1 | 2024-05-15 )
Kita pelno data ( $-0.130 ) 2024-08-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.280
(Sector) 42.63
(Industry) 24.32
ATR14 $0.00200 (0.21%)
AADI -3.55%
ABCL -5.26%
ABCM 0.04%
ABEO -1.31%
ABIO -1.53%
ABOS -5.30%
ABSI -14.32%
ABUS -2.55%
ABVX -0.22%
ACAD -0.47%
ACER -17.95%
ACET -2.22%
ACGN 1.29%
ACHL 0.23%
ACHV 1.63%
ACIU -4.23%
ACLX -1.21%
ACRV -5.10%
ACST 0.62%
ACXP -0.42%
ADAG -5.64%
ADAP -7.23%
ADGI 0.87%
ADIL -2.29%
ADMA -1.79%
ADPT 0.32%
ADTX -7.69%
ADVM -3.94%
ADXN -6.11%
AEON 11.51%
AEZS -5.44%
AFMD -5.07%
AGEN -7.50%
AGIO -3.45%
AGLE 6.66%
AGTC 0.00%
AIKI 0.85%
AIMDW 53.45%
AKBA -1.87%
AKRO -4.46%
AKTX -6.33%
AKUS 0.00%
ALBO 0.00%
ALDX -1.34%
ALEC -2.35%
ALGS -5.76%
ALKS 2.08%
ALLK 0.86%
ALLO -2.13%
ALLR -3.01%
ALNA 3.16%
ALNY -1.93%
ALPN 0.00%
ALPX 0.00%
ALRN -0.31%
ALT -3.11%
ALVR -4.43%
ALXN 0.00%
ALXO -8.32%
ALZN -12.01%
AMRN -2.58%
AMTI -3.13%
ANAB -1.64%
ANEB -5.58%
ANGN 0.00%
ANIX -0.38%
ANL 0.61%
ANNX -4.63%
ANPC -3.15%
APGE -5.23%
APGN 8.48%
APGNW 30.65%
APLM -4.73%
APLS -3.98%
APLT -4.36%
APM 1.33%
APOP 0.38%
APRE 2.44%
APTO -3.96%
APTX 3.17%
APVO -20.53%
ARAV -13.39%
ARCT -9.26%
ARDS 20.48%
ARDX -0.94%
ARGX -2.25%
ARNA 0.00%
ARPO -0.90%
ARQT -7.76%
ARTL -0.38%
ARTLW 9.80%
ARVN -2.84%
ARWR -2.86%
ASLN -12.17%
ASMB -1.49%
ASND -2.39%
ATAI -2.19%
ATHA 2.36%
ATHE -1.61%
ATHX -33.50%
ATNF 15.09%
ATOS -4.17%
ATRA -16.93%
ATXI -1.66%
ATXS -3.50%
AUPH -1.95%
AURA 0.96%
AUTL -4.22%
AVBP -1.02%
AVEO 0.00%
AVIR -2.22%
AVRO 2.10%
AVTE -93.30%
AVTX 4.08%
AVXL -1.06%
AXLA 0.00%
AXSM 3.22%
AYLA 0.00%
AZRX 2.07%
BBI 2.17%
BBIO -2.26%
BCAB -1.89%
BCDA -2.05%
BCDAW -33.33%
BCEL -1.32%
BCLI -8.47%
BCRX 1.13%
BCTX 4.96%
BCTXW 0.00%
BCYC -4.33%
BDRX 1.89%
BDTX -8.38%
BEAM -3.38%
BFRA -2.91%
BGNE -1.97%
BIOR -10.12%
BIVI 0.41%
BLCM -6.68%
BLI -5.88%
BLPH -0.79%
BLRX -3.79%
BLTE -0.72%
BLU 0.03%
BLUE -0.77%
BMEA -9.75%
BMRN 1.81%
BNOX 1.64%
BNTC 2.46%
BNTX -3.95%
BOLD -5.95%
BOLT -0.82%
BPMC -1.59%
BPTH 10.65%
BPTS -13.47%
BRNS -6.63%
BRTX 20.00%
BTAI -2.92%
BTTX -7.50%
BTX 0.05%
BVXV 0.74%
BXRX 7.39%
BYSI 6.06%
CABA -12.20%
CADL -0.96%
CALA 60.00%
CALC -1.62%
CALT 0.03%
CAPR -4.06%
CARA -27.26%
CARM -9.65%
CASI -8.04%
CATB -6.97%
CBAY 0.03%
CBIO -2.65%
CBLI -7.31%
CBUS 3.07%
CCCC -5.48%
CCXI 0.00%
CDAK 0.00%
CDIO -1.51%
CDIOW -23.08%
CDMO 5.72%
CDMOP 0.04%
CDT -6.11%
CDTTW -47.71%
CDTX -6.32%
CDXC -0.67%
CDXS -2.30%
CELC -2.79%
CELU -2.19%
CELUW -9.52%
CERC -1.68%
CERE -0.16%
CERO -7.87%
CEROW -44.78%
CFRX -27.95%
CGEM 0.74%
CGEN -5.31%
CGON -2.68%
CGTX 0.92%
CHMA -6.00%
CHRS -2.96%
CINC 0.00%
CING -1.09%
CINGW -48.24%
CKPT -4.25%
CLBS -16.75%
CLDX 0.69%
CLGN 1.19%
CLLS -4.89%
CLNN -2.48%
CLNNW -41.25%
CLRB -9.94%
CLSD -0.84%
CLSN -0.68%
CLVS 0.00%
CMMB -24.79%
CMND 1.83%
CMPI 0.00%
CMPX 5.41%
CMRA 0.40%
CMRAW 33.33%
CMRX 1.44%
CNCE 0.00%
CNSP 3.94%
CNST 0.00%
CNTA -6.39%
CNTB 3.13%
CNTX -1.02%
COCP -0.16%
COEPW -0.66%
COGT 4.45%
CORT -1.31%
COYA -6.11%
CPRX -0.40%
CRBP -11.76%
CRBU -2.23%
CRDF -1.11%
CRGX -4.78%
CRIS 1.11%
CRNX -1.37%
CRSP -2.79%
CRTX 2.63%
CRVO -1.89%
CRVS -5.39%
CSBR 1.19%
CTCX -8.04%
CTIC 0.06%
CTMX -0.72%
CTNM 0.00%
CTXR -1.50%
CUE -1.47%
CVAC -5.18%
CVKD 3.18%
CWBR -2.55%
CYAD -12.96%
CYCC -3.55%
CYCCP -1.79%
CYCN 6.00%
CYT -2.27%
CYTK -2.13%
CYTO 2.48%
DARE -3.31%
DAWN -4.60%
DBTX -0.81%
DBVT 1.01%
DFFN 10.28%
DICE 0.06%
DMAC -0.42%
DNLI -1.21%
DNTH -2.85%
DOMH 1.99%
DRMA 0.00%
DRMAW 0.00%
DRNA 0.00%
DRTS -1.32%
DRTSW 1.01%
DRUG 0.00%
DSGN 2.97%
DTIL -2.07%
DYAI -5.29%
EARS -1.77%
EDIT 0.20%
EDSA 1.04%
EFTR -3.13%
EFTRW -0.26%
EIGR 0.00%
ELAB 1.44%
ELDN -6.93%
ELEV -7.89%
ELOX -12.50%
ELTX -2.33%
ELVN -0.65%
ELYM -13.05%
ENGN -3.89%
ENGNW -7.06%
ENLV -3.47%
ENOB 1.79%
ENSC -0.55%
ENTA -6.00%
ENTO -2.80%
ENTX 0.00%
ENVB -4.64%
EPIX -8.75%
EPRX -0.19%
EPZM 0.00%
EQ 0.50%
EQRX -2.09%
EQRXW 0.00%
ERAS -7.83%
ERNA 2.60%
ERYP 1.30%
ESLA -6.38%
ESLAW -9.25%
ETNB 1.03%
ETON -5.90%
ETTX 0.00%
EVAX -19.54%
EVGN -2.14%
EVLO 50.00%
EWTX -0.80%
EXAI 1.19%
EXEL 0.18%
EYEG -0.43%
EYEN 1.57%
EYPT -3.94%
FATE -1.11%
FBIO 1.60%
FBIOP -1.05%
FBLG -5.34%
FBRX -7.46%
FDMT 0.72%
FENC 0.74%
FGEN -5.36%
FHTX 9.52%
FIXX 0.77%
FMTX 0.00%
FNCH -6.25%
FOLD -0.99%
FREQ 4.76%
FRLN 0.15%
FRTX -0.54%
FSTX 0.00%
FTRE 0.38%
FULC -6.04%
FUSN 0.00%
FWBI 4.59%
FWP 0.00%
GALT -4.58%
GANX 6.45%
GBIO 6.57%
GBT 0.01%
GDTC 2.16%
GERN -4.11%
GHRS 3.42%
GLMD -6.66%
GLPG 1.18%
GLSI 18.16%
GLTO -4.90%
GLUE -4.18%
GLYC -9.70%
GMAB -1.57%
GMDA 0.00%
GMTX 0.00%
GNCA -85.71%
GNFT 0.14%
GNLX 1.27%
GNPX 1.84%
GNTA -0.60%
GOSS 0.02%
GOVX -7.50%
GOVXW -24.72%
GPCR 0.85%
GRAY -10.80%
GRCL 0.05%
GRNA -0.03%
GRNAW 8.91%
GRPH -2.75%
GRTS -2.71%
GRTX -4.26%
GTHX -3.96%
GUTS -3.90%
GXGXW 41.67%
GYRE 4.44%
HALO 0.32%
HARP 0.09%
HCWB -9.73%
HEPA -6.36%
HGEN -84.62%
HILS 5.66%
HLVX 1.33%
HOOK -4.04%
HOTH -3.73%
HOWL 3.99%
HRMY 1.10%
HRTX -10.42%
HSTO 62.16%
HUMA -12.20%
HUMAW -5.97%
IBRX -2.18%
ICCC 2.84%
ICPT 0.21%
ICU 1.30%
ICUCW -10.39%
ICVX -0.91%
IDRA -23.04%
IDYA -1.44%
IFRX -3.21%
IGMS 0.41%
IKNA -0.57%
IKT 8.90%
IMAB -1.09%
IMCR -3.82%
IMGN 0.02%
IMGO 0.00%
IMMP -0.74%
IMMX -0.49%
IMNM -11.86%
IMNN -1.80%
IMPL -27.27%
IMRA 15.96%
IMRN -2.78%
IMRX 1.66%
IMTX -0.08%
IMTXW -2.70%
IMUX -4.20%
IMV 0.00%
IMVT 3.08%
INAB -8.26%
INBX -9.62%
INCY 0.93%
INDP 7.98%
INFI -52.38%
INKT -1.05%
INM -2.58%
INMB -2.47%
INO -1.65%
INSM 1.22%
INTS -5.63%
INVA 1.57%
INZY -2.95%
IOBT -6.11%
IONS 0.27%
IOVA -0.98%
IPA 0.48%
IPHA -10.64%
IPSC 0.64%
IRON -3.05%
ISEE 0.38%
ITOS -6.04%
ITRM -1.74%
IVA -10.10%
IVVD -6.96%
JAGX -6.67%
JANX -4.57%
JAZZ 1.43%
JNCE 0.00%
JSPR -2.80%
JSPRW 2.33%
JUNS 0.00%
JUNSW 0%
KA 4.11%
KALV -2.07%
KDNY 0.22%
KMPH -0.34%
KNSA -1.28%
KNTE -0.38%
KOD -4.27%
KPRX -21.08%
KPTI 1.69%
KRBP 4.17%
KRON -3.70%
KROS -9.68%
KRRO -16.54%
KRTX 0.03%
KRYS -0.04%
KTRA -2.35%
KTTA -2.85%
KTTAW 8.62%
KURA -0.62%
KYMR -4.42%
KYTX -17.21%
KZIA -1.29%
KZR -2.71%
LABP 0.57%
LBPH 1.67%
LBPS 0.00%
LBPSW 14.81%
LEGN -2.24%
LENZ -0.54%
LEXX -5.18%
LEXXW -9.42%
LGND 0.72%
LGNDV 0.00%
LGVN -24.76%
LIAN 0.00%
LIFE 2.70%
LIPO -1.23%
LIXT 0.40%
LIXTW 27.74%
LJPC -0.32%
LMNL 0.12%
LOGC 2.76%
LPCN 12.64%
LPTX -1.90%
LQDA 3.01%
LRMR -14.91%
LSTA -4.97%
LTRN -8.57%
LUMO -2.95%
LVTX -9.52%
LXEO -6.50%
LXRX -5.49%
LYEL -8.05%
LYRA -8.37%
MACK 0.00%
MBIO 476.92%
MBRX -4.83%
MCRB -5.28%
MDGL -0.31%
MDNA -13.16%
MDWD 1.00%
MDXG 0.59%
MEIP 1.41%
MESO -0.55%
MGNX -4.03%
MGTA -7.74%
MGTX -2.23%
MGX -24.14%
MIRM 27.31%
MIRO 0.59%
MIST -1.42%
MITO 0.00%
MLEC -4.55%
MLECW 9.20%
MLND -5.36%
MLTX -2.99%
MLYS -3.02%
MNKD -1.04%
MNMD -3.36%
MNOV 0.00%
MNPR -8.51%
MOLN 8.81%
MOR 0.88%
MORF -1.25%
MREO 0.00%
MRKR 16.59%
MRNA -1.52%
MRNS -1.02%
MRSN -1.45%
MRTX -0.17%
MRUS -1.38%
MRVI -3.99%
MTCR -1.29%
MTEM 1.54%
MTP -18.50%
MURA 2.17%
MYMD 4.19%
NAMS -7.03%
NAMSW -7.61%
NAUT 0.00%
NBRV 0.71%
NBSE -1.56%
NBTX 4.77%
NCNA -1.64%
NERV 8.96%
NEXI 0.00%
NGM -1.28%
NGNE -6.08%
NKGN -4.44%
NKGNW 39.76%
NKTR 0.00%
NKTX -5.66%
NLSP 30.09%
NLSPW -16.67%
NMRA -4.09%
NMTR -42.97%
NOVN -24.84%
NRBO 0.45%
NRIX 0.72%
NRSN -3.82%
NRSNW 6.50%
NRXP 0.99%
NRXPW -15.65%
NRXS -6.06%
NTBL 13.82%
NTEC -12.45%
NTHI 0%
NTLA 0.08%
NTRBW -6.25%
NUVL -0.77%
NVAX -2.43%
NVCT 1.18%
NVIV -34.28%
NXTC -10.63%
NYMX -0.05%
OABI 0.95%
OABIW 13.46%
OBIO 0.88%
OBSV 0.00%
OCEA 10.64%
OCGN -5.63%
OCS -1.09%
OCUL -4.35%
OCUP 1.82%
ODT -4.27%
OKYO 0.00%
OLMA -3.96%
OMER -0.49%
OMGA -8.37%
ONCO 12.54%
ONCR -3.08%
ONCS 31.87%
ONCT -0.12%
ONCY -0.98%
ONTX -0.47%
ONVO 0.62%
OPNT 0.00%
OPT -5.51%
ORGS -1.72%
ORIC -0.67%
ORMP -0.44%
ORPH 0.00%
ORTX 0.30%
OSMT -1.77%
OTIC -92.64%
OTLK -1.43%
OVID -76.00%
OYST 0.00%
PALI 0.86%
PASG -3.81%
PBLA 9.76%
PBM -0.02%
PBYI 2.89%
PCSA 5.71%
PCVX -1.45%
PDSB -4.13%
PEPG 0.70%
PGEN 0.00%
PHAR 2.17%
PHAS 0.00%
PHAT 3.08%
PHIO 4.14%
PHIOW 36.47%
PHVS -0.53%
PHXM -5.20%
PIRS -5.64%
PKBO 0.00%
PKBOW 999 900.00%
PLRX -5.08%
PLUR 0.00%
PMN -5.59%
PMVP -1.20%
PNT 0.16%
PPBT -11.48%
PRAX -6.21%
PRDS 0.93%
PRLD 0.77%
PROG -3.47%
PROK 6.96%
PRQR -3.41%
PRTA -0.20%
PRTC -0.72%
PRTG -1.96%
PRTK 1.83%
PRVB 0.00%
PSTI -2.91%
PSTV 0.00%
PSTX 1.81%
PTCT -1.14%
PTE -0.82%
PTGX -2.76%
PTIXW 2.50%
PULM 3.72%
PXMD -1.92%
PYPD -0.36%
PYXS -3.43%
QLGN -11.72%
QNCX 0.00%
QNRX -10.97%
QSI -2.92%
QSIAW 0.00%
QTTB 3.82%
QURE -4.09%
RAIN -1.63%
RANI -5.46%
RAPT -0.30%
RARE 1.92%
RCKT -3.02%
REGN 0.85%
RENB -3.05%
REPL -6.63%
RETA 0.02%
REUN -0.89%
REVB 1.36%
REVBU 3.46%
REVBW 25.20%
RGLS -1.66%
RGNX -6.20%
RIGL -2.79%
RLAY -3.01%
RLMD -0.33%
RLYB -6.15%
RNA -0.10%
RNAC -14.55%
RNAZ -5.83%
RNXT 14.41%
ROIV 0.28%
ROIVW 4.56%
RPHM -0.60%
RPRX -1.15%
RPTX 0.00%
RUBY 2.70%
RVLP -32.05%
RVMD -3.94%
RVMDW -23.93%
RVNC -0.71%
RVPH -0.68%
RVPHW 11.54%
RXDX 0.09%
RXRX 1.19%
RYTM -3.76%
RYZB 0.02%
RZLT -2.53%
SABS 3.17%
SABSW -32.14%
SAGE -6.08%
SANA -1.32%
SAVA 0.81%
SAVAW 0.00%
SBBP 1.52%
SBTX 1.03%
SCNI 60.46%
SCPH -1.69%
SCPS 0.00%
SEEL -4.62%
SEER -3.37%
SELB -8.00%
SESN 7.29%
SGEN -0.07%
SGMO -17.30%
SGMT 1.93%
SGTX -2.56%
SIOX 22.63%
SLDB -5.44%
SLGL -2.22%
SLN -1.55%
SLNO 0.19%
SLRX 2.89%
SLS -16.67%
SMMT -5.84%
SNDX -1.14%
SNGX -5.91%
SNPX -3.97%
SONN -4.75%
SPPI -0.49%
SPRB 0.49%
SPRC -3.16%
SPRO -5.88%
SRNE 20.00%
SRPT -4.89%
SRRA 0.00%
SRRK -7.09%
SRZN -1.70%
STAB 0.00%
STOK -4.00%
STRO -7.51%
STSA 0.00%
STTK -19.55%
SURF -0.93%
SVRA -5.15%
SWTX -4.88%
SYBX -0.63%
SYRS -4.83%
TALS -0.73%
TARA -0.78%
TARS -6.91%
TBPH -0.59%
TCBP -8.64%
TCDA 0.00%
TCON 6.35%
TCRR 0.00%
TCRT 1.05%
TCRX -11.43%
TECH -1.40%
TENX -3.43%
TERN -2.93%
TFFP 0.52%
TGTX 0.12%
THRX 0.12%
TIL -2.06%
TLC 0.00%
TLSA 5.78%
TNGX 5.04%
TNXP -2.61%
TNYA -1.79%
TPST 0.34%
TRDA -3.61%
TRVI 2.08%
TRVN -1.88%
TSHA 1.51%
TSVT 3.29%
TTNP 1.45%
TVTX 2.23%
TYRA -8.69%
UBX -4.17%
UNCY 0.22%
URGN -4.79%
UTHR 3.12%
VACC 11.36%
VALN -1.55%
VAXX -0.11%
VBIV -3.61%
VBLT -8.77%
VCEL -1.37%
VCNX -3.70%
VCYT 1.96%
VERA -0.83%
VERU 2.29%
VERV -2.77%
VIGL -2.08%
VINC -4.90%
VIR -5.85%
VIRI 4.95%
VIRX -3.62%
VKTX 0.00%
VLON -13.04%
VNDA 1.76%
VOR 1.74%
VRCA 0.49%
VRDN -1.93%
VRNA 10.04%
VRPX 10.77%
VRTX -1.46%
VSTM 0.00%
VTGN -2.84%
VTVT -0.10%
VTYX -4.51%
VXRT -8.25%
VYGR -2.94%
VYNE 2.16%
VYNT 7.78%
WINT 7.98%
WVE -3.85%
XBIO 6.75%
XBIT -0.33%
XCUR -3.10%
XENE -1.75%
XERS -0.91%
XFOR -2.75%
XLO -6.86%
XLRN 0.00%
XNCR -5.15%
XOMA -4.31%
XOMAO 0.68%
XOMAP -0.14%
XRTX 1.96%
YMAB -1.34%
ZGNX 0.00%
ZIOP -0.88%
ZLAB 1.55%
ZNTL -5.09%
ZSAN 0.00%
Insider Trading
Date Person Action Amount type
2024-03-08 Ecor1 Capital, Llc Buy 0 Ordinary Shares
2024-03-18 Piccina Cintia Buy 5 088 864 Option to purchase Ordinary Shares
2024-03-18 Piccina Cintia Buy 1 130 832 Option to purchase Ordinary Shares
2024-01-17 Rawcliffe Adrian Sell 30 080 American Depositary Shares representing Ordinary Shares
2024-01-16 Rawcliffe Adrian Sell 9 304 American Depositary Shares representing Ordinary Shares
INSIDER POWER
96.11
Last 96 transactions
Buy: 71 750 188 | Sell: 1 254 319
Koreliacija (AI algo v.1.1b): Undervalued: 0.61% $0.946 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.40 (neutral)
Trumpas: -0.63 (weak negative)
Signal:(55.054) Neutral

Adaptimmune Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
OZEM1
NESRW0.929
BUJA0.921
AITR0.921
AAIDX0.915
SENEB0.914
RENE0.907
ANSC0.896
JAJWX0.894
ATMV0.892
10 Labiausiai neigiamai susiję koreliacijos
RDZN-0.939
BTCT-0.932
RENB-0.929
PAX-0.927
ICUCW-0.926
INDV-0.926
IBAC-0.923
AIXI-0.922
CHNR-0.905
KITT-0.904

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Adaptimmune Therapeutics Koreliacija - Valiuta/Žaliavos

The country flag -0.54
( weak negative )
The country flag -0.61
( weak negative )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.66
( moderate )

Adaptimmune Therapeutics Finansinės ataskaitos

Annual 2023
Pajamos: $60.51M
Bruto pelnas: $50.66M (83.71 %)
EPS: $-0.570
FY 2023
Pajamos: $60.51M
Bruto pelnas: $50.66M (83.71 %)
EPS: $-0.570
FY 2022
Pajamos: $27.15M
Bruto pelnas: $-100.58M (-370.48 %)
EPS: $-1.030
FY 2021
Pajamos: $6.15M
Bruto pelnas: $6.15M (100.00 %)
EPS: $-1.020

Financial Reports:

No articles found.

Adaptimmune Therapeutics Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.

Total Execution Time: 1.9224300384521 seconds
Number of API calls: 3
Number of DB calls: 9